Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma
- Conditions
- First Posted Date
- 2006-07-11
- Last Posted Date
- 2008-08-26
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 39
- Registration Number
- NCT00350961
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇩🇰Vejle Sygehus, Vejle, Denmark
Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2015-12-14
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 18
- Registration Number
- NCT00347438
- Locations
- 🇳🇬
Obafemi Awolowo University, Ile-Ife, Nigeria
🇺🇸University of Chicago, Chicago, Illinois, United States
🇳🇬University of Ibadan, Ibadan, Nigeria
Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-06-28
- Last Posted Date
- 2010-08-16
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 64
- Registration Number
- NCT00345761
- Locations
- 🇯🇵
Tokai Region, Tokai, Japan
🇯🇵Hokkaido Region, Hokkaido, Japan
🇯🇵Kanto Region, Kanto, Japan
1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.
- Conditions
- First Posted Date
- 2006-06-28
- Last Posted Date
- 2011-08-24
- Target Recruit Count
- 32
- Registration Number
- NCT00345696
- Locations
- 🇪🇸
Hospital 12 de Octubre, Madrid, Spain
The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-06-27
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 84
- Registration Number
- NCT00345059
- Locations
- 🇮🇹
Ospedali Riuniti, Foggia, FG, Italy
🇮🇹Ospedale Civile di Legnano, Legnano, MI, Italy
🇮🇹Ospedale S. Paolo, Milano, MI, Italy
Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT00338988
- Locations
- 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States
Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 69
- Registration Number
- NCT00338039
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
- Conditions
- Interventions
- First Posted Date
- 2006-06-15
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1276
- Registration Number
- NCT00337103
- Locations
- 🇧🇪
Institut Jules Bordet, Medical Oncology Unit, Brussels, Belgium
🇦🇺Royal Perth Hospital, Perth, Western Australia, Australia
🇦🇺Bankstown Hospital, Oncology Trials Unit, Bankstown, New South Wales, Australia
S0425 Oxaliplatin, Capecitabine, and RT in Treating Patients W/Stomach Cancer That Can Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2006-06-12
- Last Posted Date
- 2012-08-17
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 7
- Registration Number
- NCT00335959
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸Munson Medical Center, Traverse City, Michigan, United States
🇺🇸Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler, Savannah, Georgia, United States
Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2016-05-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 34
- Registration Number
- NCT00327743
- Locations
- 🇫🇷
Sanofi-Aventis Administrative Office, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.